American Century Companies Inc. Raises Stock Holdings in Amgen Inc. $AMGN

American Century Companies Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 18.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 195,633 shares of the medical research company’s stock after buying an additional 30,511 shares during the quarter. American Century Companies Inc.’s holdings in Amgen were worth $55,208,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Rafferty Asset Management LLC raised its stake in Amgen by 0.8% during the 3rd quarter. Rafferty Asset Management LLC now owns 131,561 shares of the medical research company’s stock worth $37,127,000 after acquiring an additional 1,070 shares during the period. Harvest Portfolios Group Inc. increased its stake in shares of Amgen by 1.5% in the third quarter. Harvest Portfolios Group Inc. now owns 204,874 shares of the medical research company’s stock worth $57,815,000 after purchasing an additional 3,073 shares in the last quarter. Dunhill Financial LLC raised its position in shares of Amgen by 5.2% during the 3rd quarter. Dunhill Financial LLC now owns 1,117 shares of the medical research company’s stock valued at $315,000 after purchasing an additional 55 shares during the period. Creative Financial Designs Inc. ADV lifted its stake in shares of Amgen by 7.8% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 7,097 shares of the medical research company’s stock valued at $2,003,000 after buying an additional 515 shares in the last quarter. Finally, Ibex Wealth Advisors boosted its holdings in Amgen by 0.8% in the 3rd quarter. Ibex Wealth Advisors now owns 28,801 shares of the medical research company’s stock worth $8,128,000 after buying an additional 242 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent analyst reports. Truist Financial raised their price target on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Argus increased their target price on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. DZ Bank boosted their price target on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Finally, Guggenheim lifted their price objective on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $354.17.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board approved a $2.52 quarterly dividend, payable June 5, 2026, supporting income investors and signaling cash-flow confidence. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen launched a new Phase 3 subcutaneous trial to expand its blinatumomab franchise — a constructive pipeline development that could add long-term value if successful. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11; management comments (CFO and SVP of rare disease) could offer incremental guidance or pipeline color. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Coverage pieces examine post-earnings momentum and valuation (why AMGN has risen ~24% over the past year); useful for context but not single-driver news. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Neutral Sentiment: Reported short-interest data in early March appears erroneous (0 shares / NaN change); treat as noise until reliable data is posted. (No link available)
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals tying OX40 modulation to potential malignancies — this removes a late‑stage asset and raises near-term pipeline risk and uncertainty around R&D priorities. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: An analyst downgrade recommended waiting for a better entry point (rating cut / hold), which can amplify selling pressure after the pipeline news. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Price Performance

AMGN stock opened at $367.60 on Friday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a fifty day simple moving average of $352.53 and a two-hundred day simple moving average of $321.90. The firm has a market capitalization of $198.16 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 3.76 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.